Exchange: NYSE
Industry: Food & Drug Retailers
Last Trade: 4:00 PM ET 5/21/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 02/13 |
Fiscal Q3 Ending 11/12 |
Fiscal Q2 Ending 08/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q4 Ending 02/12 |
|
Sales/Revenue |
0 | 7,913,000 | 8,039,000 | 10,590,000 | 8,231,000 |
Cost of Goods Sold (COGS) incl. D&A |
0 | 6,234,000 | 6,319,000 | 8,265,000 | 6,353,000 |
COGS excluding D&A |
0 | 6,033,000 | 6,043,000 | 7,989,000 | 6,135,000 |
Depreciation & Amortization Expense |
NA | 201,000 | 276,000 | 276,000 | 218,000 |
Gross Income |
0 | 1,679,000 | 1,720,000 | 2,325,000 | 1,878,000 |
SG&A Expense |
0 | 1,522,000 | 1,673,000 | 2,116,000 | 1,659,000 |
Research & Development |
0 | 0 | 0 | 0 | 0 |
Other SG&A |
0 | 1,522,000 | 1,673,000 | 2,116,000 | 1,659,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
NA | 0 | 88,000 | 0 | 526,000 |
Non Operating Income/Expense |
0 | 0 | 0 | 0 | 0 |
Equity in Affiliates (Pretax) |
NA | NA | 0 | 0 | NA |
Interest Expense |
NA | 126,000 | 141,000 | 155,000 | 115,000 |
Gross Interest Expense |
NA | 126,000 | 141,000 | 155,000 | 115,000 |
Pretax Income |
-329,000 | 31,000 | -182,000 | 54,000 | -422,000 |
Income Tax |
-120,000 | 15,000 | -71,000 | 13,000 | 2,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-209,000 | 16,000 | -111,000 | 41,000 | -424,000 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-209,000 | 16,000 | -111,000 | 41,000 | -424,000 |
Extraordinaries & Discontinued Operations |
-1,203,000 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
-1,203,000 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
994,000 | 16,000 | -111,000 | 41,000 | -424,000 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-209,000 | 16,000 | -111,000 | 41,000 | -424,000 |
Operational EPS |
-0.99 | 0.07 | -0.23 | 0.19 | -0.26 |
EPS (basic) |
-6.66 | 0.08 | -0.52 | 0.19 | -1 |
EBITDA |
-314,000 | 358,000 | 323,000 | 485,000 | 437,000 |
Depreciation & Amortization Expense |
NA | 201,000 | 276,000 | 276,000 | 218,000 |
Common Shares Outstanding |
212,000 | 214,000 | 212,000 | 214,000 | 212,000 |
Basic Shares Outstanding |
212,000 | 212,000 | 212,000 | 212,000 | 212,000 |
Diluted Shares Outstanding |
212,000 | 214,000 | 212,000 | 214,000 | 212,000 |
Diluted EPS after Extraordinary Items |
-6.66 | 0.07 | -0.52 | 0.19 | -1 |
Discont. Operations Per Share |
-5.67 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.99 | 0.08 | -0.52 | 0.19 | -1 |
*Figures in thousands of U.S. Dollars except shares outstanding.
